טוען...
Hair and Nail Changes during Long-Term Therapy with Ibrutinib for Chronic Lymphocytic Leukemia
IMPORTANCE: Ibrutinib (Imbruvica(®)), a Bruton tyrosine kinase (BTK) inhibitor, is a new targeted agent approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström macroglobulinemia. Ibrutinib is overall well-tolerate...
שמור ב:
| הוצא לאור ב: | JAMA Dermatol |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6415534/ https://ncbi.nlm.nih.gov/pubmed/26982511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2016.0225 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|